VivoSim Labs, INC. VIVS
VivoSim Labs, Inc. ("VivoSim," "we," "us," "our," the "Company" and "our Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies ("NAM") models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $131.0K | $144.0K | $109.0K | $370.0K | $1.5M | $0 | $2.2M | $3.1M | $4.6M | $4.2M |
| Cost of revenue | $0 | $5.0K | — | — | — | $0 | $300.0K | $500.0K | $1.0M | $956.0K |
| Gross profit | $131.0K | $139.0K | — | — | — | $0 | $1.9M | $2.6M | $3.6M | $3.3M |
| R&D | $4.2M | $5.0M | $5.5M | $8.9M | $3.3M | $1.1M | $5.3M | $14.8M | $18.0M | $19.5M |
| SG&A | $7.4M | $7.7M | $9.7M | $9.2M | $9.7M | $15.7M | $18.1M | $15.1M | $20.9M | $22.3M |
| Total operating expenses | $11.6M | $12.8M | $15.2M | $18.1M | $13.0M | $16.8M | $23.7M | $30.4M | $39.9M | $42.8M |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M | -$11.5M | -$16.8M | -$21.5M | -$27.3M | -$35.3M | -$38.6M |
| Interest expense | $12.0K | $10.0K | — | — | — | — | — | — | — | $0 |
| Pre-tax income | -$13.8M | -$2.5M | -$14.7M | -$17.3M | -$11.4M | -$16.8M | -$18.7M | -$26.6M | -$34.8M | -$38.4M |
| Income tax | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $3.0K | $2.0K | $23.0K |
| Net income | -$13.8M | -$2.5M | -$14.7M | -$17.3M | -$11.4M | -$16.8M | -$18.7M | -$26.6M | -$34.8M | -$38.4M |
| EPS, basic | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 | — | — | — | — | — |
| EPS, diluted | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 | -2.44 | -2.80 | -0.23 | -0.32 | -0.39 |
| Shares, diluted (wtd. avg.) | $2.6M | $1.5M | $762.1K | $8.7M | $8.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.0M | $11.3M | $2.9M | $15.3M | $28.7M | $37.4M | $27.4M | $36.5M | $43.7M | $62.8M |
| Receivables | $32.0K | $30.0K | $33.0K | $152.0K | $0 | $0 | $111.0K | $503.0K | $883.0K | $647.0K |
| Inventory | — | $0 | $297.0K | $0 | — | — | $0 | $490.0K | $842.0K | $550.0K |
| Total current assets | $6.6M | $12.1M | $3.9M | $17.0M | $29.5M | $38.4M | $28.3M | $38.6M | $46.8M | $65.1M |
| Property, plant and equipment | $206.0K | $419.0K | $669.0K | $902.0K | $662.0K | $381.0K | $0 | $1.8M | $2.8M | $3.8M |
| Total assets | $7.4M | $14.7M | $6.3M | $20.3M | $33.3M | $39.9M | $28.4M | $40.6M | $49.8M | $69.2M |
| Accounts payable | $1.0M | $1.6M | $627.0K | $331.0K | $415.0K | $281.0K | $720.0K | $628.0K | $464.0K | $1.2M |
| Total current liabilities | $2.8M | $3.7M | $1.9M | $3.7M | $1.4M | $721.0K | $1.8M | $3.7M | $4.7M | $6.0M |
| Total liabilities | $8.5M | $4.2M | $2.7M | $5.0M | $3.1M | $721.0K | $1.8M | $4.3M | $5.2M | $6.8M |
| Retained earnings | -$356.0M | -$342.2M | -$339.7M | -$325.0M | -$307.7M | -$296.3M | -$279.5M | -$260.8M | -$234.1M | -$199.3M |
| Total equity | -$1.1M | $10.5M | $3.6M | $15.3M | $30.2M | $39.2M | $26.6M | $36.3M | $44.6M | $62.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.4M | -$8.5M | -$13.3M | -$14.9M | -$20.4M | -$28.9M | -$29.2M |
| Depreciation and amortisation | $215.0K | $266.0K | $280.0K | $293.0K | $142.0K | $41.0K | $1.1M | $980.0K | $1.3M | $1.1M |
| Stock-based compensation | — | — | — | — | — | — | — | — | $6.9M | $7.4M |
| Capital expenditure | $0 | $13.0K | $42.0K | $396.0K | $409.0K | $405.0K | $0 | $79.0K | $226.0K | $1.4M |
| Investing cash flow | $94.0K | $9.0M | $816.0K | -$966.0K | -$409.0K | -$393.0K | $747.0K | -$76.0K | -$292.0K | -$1.4M |
| Financing cash flow | $4.4M | $8.8M | $1.4M | $0 | $205.0K | $23.8M | $4.9M | $13.2M | $10.1M | $31.2M |
| Buybacks | — | — | — | — | $0 | $1.0K | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-361066.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |